Abstract
Modern biology and medicine have been accumulating facts that many human diseases, including the most widespread (cardiovascular, oncological, etc.), are directly or indirectly related to defects of the human genome, and primarily, to defects of the structure of the genes that code vitally important proteins. The repair of genome defects opens the way to a radical cure. This explains the appearance of gene therapy—the introduction of “healthy” genes into the cells of patients. However, the experience of the last decade has demonstrated that progress here is much slower than had been expected. Based on the results of his studies and the generalization of world literature, the author suggests an alternative to gene therapy: correction of gene defects during the synthesis of the gene product—the protein—rather than at the genomic level. The paper discusses the advantages and disadvantages of the new approach, which the author calls “translation therapy.”
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
M. S. Gel’fand and V. A. Lyubetskii, “Bioinformatics: From Experiment to Computer Analysis and Back to Experiment Again,” Vestn. Ross. Akad. Nauk 73, 987–994 (2003) [Herald of the RAS 73 (6), 626–632 (2003)]; Yu. M. Evdokimov, “Mesomorphic Forms of Nucleic Acids,” Vestn. Ross. Akad. Nauk 73, 712–721 (2003); A. V. Zelenin, “The Plant Genome,” Vestn. Ross. Akad. Nauk 73, 797–806 (2003) [Herald of the RAS 73 (5), 523–531 (2003)]; P. L. Ivanov, “Human Individualization and Personal Identification: Molecular Biology in Forensic Medicine,” Vestn. Ross. Akad. Nauk 73, 1085–1097 (2003) [Herald of the RAS 73 (6), 633–643 (2003)]; V. L. Karpov, “DNA, Chromatin, and the Histone Code,” Vestn. Ross. Akad. Nauk 73, 505–513 (2003) [Herald of the RAS 73 (3), 270–277 (2003)]; L. L. Kiselev, “The DNA Double Helix: The Symbol and the Foundation of New Biology,” 73, 919–928 (2003) [Herald of the RAS 73 (5), 532–550 (2003)]; E. D. Sverdlov, “DNA in a Cell: From a Molecular Icon to the Problem of ‘What Is Life?’,” Vestn. Ross. Akad. Nauk 73, 497–504 (2003) [Herald of the RAS 73 (3), 262–269 (2003)]; E. K. Khusnutdinova, “The Ethnogenomics and Genetic History of Eastern European Peoples,” Vestn. Ross. Akad. Nauk 73, 614–621 (2003) [Herald of the RAS 73 (4), 365–372 (2003)].
Mol. Biol. 38, 5–238 (2004).
Genomics for the Medicine, Ed. by V. I. Ivanova and L. L. Kiseleva (NKTs Akademkniga, Moscow, 2005) [in Russian].
Gene Therapy for the Future Medicine, Ed. by A. V. Zelenin (VINITI, Moscow, 2000) [in Russian].
L. L. Kiselev, N. Yu. Oparina, and L. Yu. Frolova, “Class-1 Polypeptide Chain Release Factors Are Structurally and Functionally Similar to Suppressor tRNAs and Comprise Different Structural-Functional of Prokaryotic/Mitochondrial and Eukaryotic/Archaebacterial Factors,” Mol. Biol. 34, 427–441 (2000).
J. Carnes, L. Frolova, S. Zinnen, et al., “Suppression of Eukaryotic Translation Termination by Selected RNAs,” RNA 6, 1468–1479 (2000).
J. Carnes, M. Jacobson, L. Leinwand, and M. Yarus, “Stop Codon Suppression via Inhibition of ERF1 Expression,” RNA 6, 648–653 (2003).
E. Ilegems, H. M. Pick, and H. Vogel, “Downregulation of eRF1 by RNa Interference Increases Mis-Acylated tRNA Suppression Efficiency in Human Cells,” Protein Eng. Des. Sel. 12, 821–827 (2004).
P. Y. Lu, F. Xie, and M. C. Woodle, “In Vivo Application of RNA Interference: from Functional Genomics to Therapeutics,” Adv. Genet. 54, 117–42 (2005); H. H. Van Es and G. J. Arts, “Biology Calls the Targets: Combining RNAi and Disease Biology,” Drug Discov. Today 10 (20), 1385–1391 (2005).
D. M. Janzen and A. P. Geballe, “The Effect of Eukaryotic Release Factor Depletion on Translation Termination in Human Cell Lines,” Nucleic Acid Res. 15, 4491–4502 (2004).
L. Frolova, X. Le Goff, H. H. Rasmussen, S. Cheperegin, et al., “A Highly Conserved Eukaryotic Protein Family Possessing Properties of Polypeptide Chain Release Factor,” Nature 372, 701–703 (2000).
G. Bertram, H. A. Bell, D. W. Ritchie, et al., “Terminating Eukaryote Translation: Domain 1 of Release Factor ERF1 Functions in Stop Codon Recognition,” RNA 6, 1236–1247 (2000).
L. Frolova, A. Seit-Nebi, and L. Kisselev, “Highly Conserved NIKS Tetrapeptide Is Functionally Essential in Eukaryotic Translation Termination Factor eRF1,” RNA 8, 129–136 (2000).
K. Ito, L. Frolova, A. Seit-Nebi, et al., “Omnipotent Decoding Potential Resides in Eukaryotic Translation Termination Factor eRF1 of Variat-Code Organisms and Is Modulated by the Interactions of Amino Acid Sequences Within Domain 1,” Proc. Natl. Acad. Sci. USA 99, 8494–8499 (2002).
A. Seit-Nebi, L. Frolova, and L. Kisselev, “Conversion of Omnipotent Translation Termination Factor ERF1 into Ciliate-Like UGA-Only Unipotent ERF1,” EMBO Rep. 3, 881–886 (2002).
L. Chavatte, A. Seit-Nebi, V. Dubovaya, and A. Favre, “The Invariant Uridine of Stop Codons Contacts the Conserved NIKSR Loop of Human ERF1 in the Ribosome,” EMBO J. 19, 5302–5311 (2002).
P. Kolosov, L. Frolova, A. Seit-Nebi, et al., “Invariant Amino Acids Essential for Decoding Function of Polypeptide Release Factor ERF1,” Nucleic Acids Res. 33, 6418–6425 (2005).
Author information
Authors and Affiliations
Additional information
Original Russian Text © L.L. Kisselev, 2006, published in Vestnik Rossiiskoi Akademii Nauk, 2006, Vol. 76, No. 3, pp. 219–226.
Rights and permissions
About this article
Cite this article
Kisselev, L.L. Translation therapy: Is it an alternative to gene therapy?. Her. Russ. Acad. Sci. 76, 144–151 (2006). https://doi.org/10.1134/S1019331606020067
Issue Date:
DOI: https://doi.org/10.1134/S1019331606020067